


XY028-133

Cat. No.:	HY-129180
CAS No.:	2229974-73-4
Molecular Formula:	C ₅₃ H ₆₇ N ₁₁ O ₇ S
Molecular Weight:	1002.23
Target:	CDK; PROTACs
Pathway:	Cell Cycle/DNA Damage; PROTAC
Storage:	-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (49.89 mM; Need ultrasonic)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	0.9978 mL	4.9889 mL	9.9778 mL
	5 mM	0.1996 mL	0.9978 mL	1.9955 mL
	10 mM	0.0998 mL	0.4989 mL	0.9978 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	XY028-133 (example 14) is a PROTAC-based CDK4/6 degrader with anti-tumor activity, which consists of ligands for von Hippel-Lindau and CDK ^[1] .	
IC₅₀ & Target	CDK4	CDK6
In Vitro	XY028-133 (1 and 3 μM, 24 h) significantly decreases CDK4/6, Cyclin A, PLK1 and pRb protein levels in A375 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. JIN, Jian et al. COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER. Patent. US2017/065027.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA